Il s'agit de notre dernière sélection de publications et de brevets mondiaux en anglais sur la biotechnologie et CRISPR, parmi de nombreuses revues scientifiques en ligne, classées et axées sur CRISPR, l'édition de gènes, l'ARNg, la séquence PAM, le clivage de l'ADN, la protéine Cas9, l'édition du génome, l'insertion de gènes et le knock-out de gènes.
Engineered exosomes and methods for producing the same
Patent published on the 2026-05-21 in US under Ref US20260137808 by UNIV KENTUCKY RES FOUND [US] (Tong Sheng [us], Yang Xiaoyue [us])
Abstract: [0000] Methods for producing an engineered exosome (eEXO) that make use of one or more magnetic nanoparticles (MNPs) complexed with a therapeutic payload are provided. The MNP-therapeutic payload complex is loaded into an endosome of a producer cell. The enriched endosome containing the MNP-therapeutic payload complex is extracted from the producer cell and extruded to produce the eEXO. Loading of the MNP-therapeutic payload complex and extraction of the enriched endosome can be facilitated by t[...]
Our summary: Methods for producing engineered exosomes involve loading magnetic nanoparticles with a therapeutic payload into the endosome of a producer cell. The enriched endosome is extracted and extruded to create the engineered exosomes. CRISPR ribonucleoprotein can serve as the therapeutic payload for gene editing applications.
engineered exosomes, magnetic nanoparticles, therapeutic payload, CRISPR
Patent
Use of tigit gene locus as a car integration site for generation of car expressing immune cells
Patent published on the 2026-04-23 in WO under Ref WO2026085461 by RES INST NATIONWIDE CHILDRENS HOSPITAL [US] (Campbell Amanda [us], Lee Dean [us], Kararoudi Meisam Naeimi [us])
Abstract: Disclosed are plasmid and methods for genetically engineering NK cells using a CRISPR/CAS9 system to knock out TIGIT while simultaneously knocking in a chimeric antigen receptor (CAR). In some aspects, disclosed herein are method of using such engineering NK cells for treating cancers.[...]
Our summary: The TIGIT gene locus is utilized as a CAR integration site for NK cell engineering. Methods involve using CRISPR/Cas9 to knock out TIGIT and insert a CAR. Engineered NK cells are designed for cancer treatment applications.
TIGIT, CAR, NK cells, CRISPR/Cas9
Patent
Transmembrane receptor gene editing
Patent published on the 2026-04-23 in WO under Ref WO2026085500 by ORTHOBIO THERAPEUTICS INC [US] (Millett Peter J [us], Russell Iain Alasdair [gb], Allen Matthew J [gb], Gentsch George [gb])
Abstract: Provided herein are compositions and methods for ablating intracellular signaling through specific cell surface receptors as means of treatment for various conditions of a pro-inflammatory character. In some aspects, the compositions and methods are to prevent the progression of osteoarthritis and other arthritides and to treat osteoarthritis and other arthritides in a mammalian joint. In some aspects, the compositions and method are for treating or preventing localized nociception, inflammation[...]
Our summary: This content discusses methods for editing transmembrane receptor genes to inhibit intracellular signaling. The approaches aim to treat pro-inflammatory conditions, particularly osteoarthritis and related disorders. Additionally, the methods target localized nociception and inflammation associated with back or spine issues.
gene editing, transmembrane receptors, inflammation treatment, osteoarthritis
Patent
Dcas9-krab with increased nuclear localization and stability in neurons
Patent published on the 2026-04-23 in WO under Ref WO2026084976 by CHILDRENS HOSPITAL PHILADELPHIA [US] (Shalem Ophir Haim [us], Cajka Gregory [us])
Abstract: Provided herein are fusion proteins comprising an enzymatically inactive CRISPR enzyme fused to a modulator of gene expression, where the fusion protein comprises a neuron-specific nuclear localization signal (NLS), and where the modulator of gene expression comprises a Kruppel associated box (KRAB) domain. Also provided herein are method for modulating the expression of a gene in a neuron using a CRISPR system using the fusion proteins.[...]
Our summary: The study presents fusion proteins combining an inactive CRISPR enzyme with a gene expression modulator. These proteins include a neuron-specific nuclear localization signal and a KRAB domain. Methods for gene expression modulation in neurons using these fusion proteins are also described.
Dcas9-krab, nuclear localization, gene expression, neurons
Patent
Use of inhibitors or modulators of artemis in gene editing
Patent published on the 2026-04-23 in WO under Ref WO2026083309 by ASTRAZENECA AB [SE] (Dacquay Louis [se], Choong Oi Kuan [se], Akrap Nina [se], Peterka Martin [se], Maresca Marcello [se])
Abstract: The present disclosure provides modulators or inhibitors of Artemis and their uses for promoting sequence integration into a target genomic locus in a cell by non-homologous end joining-mediated prime editing.[...]
Our summary: The disclosure presents modulators or inhibitors of Artemis. These compounds promote sequence integration into target genomic loci. The method utilizes non-homologous end joining-mediated prime editing.
Artemis, gene editing, inhibitors, prime editing
Patent
Artificial intelligence-based enzyme engineering method and system, device, and medium
Patent published on the 2026-03-26 in WO under Ref WO2026061352 by INST OF GENETICS AND DEVELOPMENTAL BIOLOGY CHINESE ACADEMY OF SCIENCES [CN] (Gao Caixia [cn], Fei Hongyuan [cn], Li Yunjia [cn])
Abstract: The present invention relates to the technical field of enzyme engineering. Disclosed are an artificial intelligence-based enzyme engineering method and system, a device, and a medium. The method comprises: on the basis of structural information of an engineered enzyme to be modified, using an inverse protein folding model to obtain a plurality of structurally compatible protein sequences on the basis of a given scaffold structure; on the basis of the plurality of structurally compatible protein[...]
Our summary: The invention presents an AI-based method for enzyme engineering. It utilizes structural information and inverse protein folding to generate compatible protein sequences. This approach facilitates the efficient creation of mutation variant sets for precise gene editing.
enzyme engineering, artificial intelligence, protein folding, gene editing
Patent
Re-evaluating the site-directed nuclease classification as a regulatory trigger for genome-edited plant products
Published on 2026-03-05 by Osman Mewett, John McMurdy, Lieselot Bertho, Ana Atanassova, Naomi Stevens, Scott Huber, Maria Fedorova, Kevin Diehl, Kevin Tianmeng Zhao @NATURE
Abstract: Nature Biotechnology, Published online: 05 March 2026; doi:10.1038/s41587-026-03028-0Site-directed nuclease (SDN) classification into SDN-1, SDN-2 and SDN-3 outcomes is used for regulating genome-edited plant products in some countries. This reductive categorization system fails to cover the breadth of genome editing technologies developed over the past decade and their rapidly approaching commercial use. Here, we argue that, in the context of plant breeding, regulations should focus on the char[...]
Our summary: The current classification of site-directed nucleases (SDNs) is inadequate for regulating genome-edited plants. A shift towards an outcome-focused regulatory approach is proposed to enhance oversight and efficiency. This change aims to address challenges in crop improvement related to climate change and pest resistance.
genome editing, site-directed nucleases, regulatory framework, plant breeding
Publication
Ethical and Clinical Best Practices for Genome Editing Applications
Published on 2026-02-02 by Mara Ortiz-Bueno, Federica Zinghirino, Pilar Puig Serra, Kyriaki Paschoudi, Lluis Montoliu, Erden Atilla, Yonglun Luo, Alessia Cavazza, Carsten W. Lederer, Karim Benabdellah @MDPI
Abstract: Genome editing (GE) has transformed medicine by allowing precise changes to DNA, offering potential treatments for a range of inherited and acquired disorders. Several technologies support these advances, including zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeats (CRISPR)-based systems, of which the latter has emerged as the most accessible, versatile, and popular. While GE holds great promise, i[...]
Our summary: Genome editing technologies enable precise DNA modifications for medical treatments. Ethical and regulatory considerations are crucial for safe clinical applications. Regulatory agencies provide guidance on safety, consent, and compliance in genome editing practices.
Genome Editing, Ethical Standards, Regulatory Compliance, Clinical Applications
Publication